\
&
Contact us
\
&
Contact us
Published on | 5 years ago
Programmes SecurityThe amount of submitted proposals and available budget of the following calls have been published:
H2020-SU-SEC-2018-2019-2020
A total of 214 proposals have been submitted in response to this call. The number of proposals for each topic is shown below including the indicative budget of the topics for 2019:
H2020-SU-DS-2018-2019-2020
A total of 80 proposals have been submitted in response to this call. The number of proposals for each topic is shown below including the indicative budget of the topics for 2019:
H2020-SU-INFRA-2018-2019-2020
A total of 48 proposals have been submitted in response to this call. The number of proposals for each topic is shown below including the indicative budget of the topics for 2019:
The evaluation of the proposals will start by mid-September and will be closed by the end of the year. Applicants will be informed on the outcome of the evaluations in mid-January 2020.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
